alendronate has been researched along with tiludronic acid in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barbier, A; Baron, R; David, P; Nguyen, H | 1 |
| Licata, AA | 1 |
| Fleisch, HA | 1 |
| Handt, LK; Peter, CP; Smith, SM | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Papapoulos, SE | 1 |
| Barbier, A; Baslé, MF; Chappard, D; Filmon, R | 1 |
| Watts, NB | 1 |
| Epstein, M; Joshua, F; Major, G | 1 |
| Boos, J; Lanvers-Kaminsky, C; Vorotnjak, M | 1 |
| Silverman, SL | 1 |
| Byard, S; Duer, MJ; Ironside, MS; Reid, DG | 1 |
7 review(s) available for alendronate and tiludronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 1997 |
Bisphosphonates: preclinical aspects and use in osteoporosis.
Topics: Alendronate; Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteoporosis; Pamidronate | 1997 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Papio; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Time Factors | 2000 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 2001 |
Paget disease of bone: therapeutic options.
Topics: Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pamidronate; Retreatment; Risedronic Acid; Treatment Outcome | 2008 |
1 trial(s) available for alendronate and tiludronic acid
| Article | Year |
|---|---|
Bisphosphonate resistance in Paget's disease of bone.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Drug Resistance; Humans; Injections, Intravenous; Middle Aged; Osteitis Deformans; Pamidronate | 2003 |
5 other study(ies) available for alendronate and tiludronic acid
| Article | Year |
|---|---|
The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
Topics: Alendronate; Animals; Binding, Competitive; Bone Resorption; Cell Membrane Permeability; Chickens; Diphosphonates; Dose-Response Relationship, Drug; Ethylmaleimide; Etidronic Acid; Female; Hydrogen-Ion Concentration; Kidney; Lethal Dose 50; Osteoclasts; Proton-Translocating ATPases; Saccharomyces cerevisiae; Synaptic Vesicles | 1996 |
Esophageal irritation due to alendronate sodium tablets: possible mechanisms.
Topics: Alendronate; Animals; Bone Resorption; Diphosphonates; Dogs; Esophagus; Etidronic Acid; Mucous Membrane; Risedronic Acid | 1998 |
Poly(2-hydroxy ethyl methacrylate)-alkaline phosphatase: a composite biomaterial allowing in vitro studies of bisphosphonates on the mineralization process.
Topics: Alendronate; Alkaline Phosphatase; Biocompatible Materials; Bone and Bones; Calcium; Cartilage; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Fetus; Glycerophosphates; Humans; Microscopy, Electron; Microscopy, Electron, Scanning; Models, Chemical; Organophosphonates; Polyhydroxyethyl Methacrylate; Tibia; Time Factors; Zinc | 2000 |
In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Topics: Alendronate; Apoptosis; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Diphosphonates; Drug Screening Assays, Antitumor; Germany; Humans; Ibandronic Acid; Imidazoles; Neuroblastoma; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Crystallization; Diphosphonates; Horses; Imidazoles; Magnetic Resonance Spectroscopy; Molecular Structure; Pamidronate; Structure-Activity Relationship; Technology, Pharmaceutical; Zoledronic Acid | 2010 |